Drug Patents owned by Mayne Pharma

1. Drug name - DORYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161 MAYNE PHARMA Modified release coated drug preparation Dec, 2022

(2 months from now)

US8715724 MAYNE PHARMA Tabletting process Feb, 2028

(5 years from now)

US9511031 MAYNE PHARMA Controlled release doxycycline Oct, 2034

(12 years from now)

US9295652 MAYNE PHARMA Controlled release doxycycline Oct, 2034

(12 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline Dec, 2034

(12 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 80MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 60MG BASE TABLET, DELAYED RELEASE;ORAL Discontinued
EQ 120MG BASE TABLET, DELAYED RELEASE;ORAL Prescription

2. Drug name - FABIOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859 MAYNE PHARMA Topical foam composition Feb, 2030

(7 years from now)

US10688071 MAYNE PHARMA Topical foam composition Feb, 2030

(7 years from now)

US8808716 MAYNE PHARMA Topical foam composition Feb, 2030

(7 years from now)

Drugs and Companies using TAZAROTENE ingredient

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1% AEROSOL, FOAM;TOPICAL Prescription

3. Drug name - LEXETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857159 MAYNE PHARMA Halobetasol foam composition and method of use thereof Nov, 2036

(14 years from now)

US11020407 MAYNE PHARMA Corticosteroid containing foam compositions and method of manufacture thereof Nov, 2036

(14 years from now)

US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof May, 2037

(14 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% AEROSOL, FOAM;TOPICAL Prescription

4. Drug name - NEXTSTELLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception Mar, 2025

(2 years from now)

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG;14.2MG TABLET;ORAL Prescription

5. Drug name - SORILUX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629128 MAYNE PHARMA Vitamin formulation May, 2026

(3 years from now)

US8263580 MAYNE PHARMA Vitamin formulation May, 2028

(5 years from now)

Drugs and Companies using CALCIPOTRIENE ingredient

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older; Use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.005% AEROSOL, FOAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.